# Widecells Group PLC Q&A with Chief Executive Officer João Andrade (LON:WDC)

- Link: https://www.directorstalkinterviews.com/widecells-group-plc-qa-chief-executive-officer-joao-andrade-lonwdc/412726613
- Published: 2017-04-03T11:51:35+01:00
- Author: Amilia Stone

**Widecells Group PL**C (LON:WDC) Chief Executive Officer João Andrade caught up
with DirectorsTalk for an exclusive interview to discuss why they are focussing 
on the stem cell industry, their new laboratory in Manchester, the launch of CellPlan&
their very strong Board

 

**Q1: I know Widecells is focussed on supporting the stem cell industry but can 
you provide us a bit more information about how you’re looking to achieve this and
why you’re focussing on this market?**

**A1**: Well, the main reason why I focus on this market and I started Widecells
is because stem cell technology has been around for more than forty years now and
there’s lack of information, even within the healthcare community, unfortunately,
about the benefits and possibilities for treatment for patients worldwide using 
stem cell technology. Because this technology is available we know which hospitals
and treatment centres are performing these treatments, we know the medical teams
that are involved in this treatment as well, we have built services and solutions
to allow patients from all over the world to access this technology with lifesaving
potential.

 

**Q2: In Manchester, you’re developing your own laboratory, both to support advancements
in stem cells technology and for storage. Now, in your results, the accounts show
capex investment of £360,000, is this what a stem cell bank would usually cost to
set up?**

**A2**: I have to say that we’ve been very fortunate with the selection of the location
for the uses for stem cell technology because what we have found at the University
of Manchester Innovation Centre, which is a premium location, is clean rooms that
were available. We made this investment to upgrade the clean rooms and also to re-
equip the whole lab so that we can process and store stem cells for period of up
to thirty years and also to support stem cell research companies.

Now, regarding your question about the usual investment for stem cell bank, normally
it would be around £1.5-£2 million in the UK. I must say that for the quality of
the facilities that Widecells have set up, the quality management system we have,
which we share with the University of Manchester, we have a really high quality 
standard facility. We can operate with the best stem cell research companies in 
the world and provide reassurance to parents who will be looking to store stem cells
with us, that they will be stored in appropriate conditions for period of thirty
years. So, it was a great investment opportunity and the money we raised at the 
IPO would normally be the necessary funds just for the stem cell bank itself, whilst
with the same money we’ve built three different divisions and we are now at the 
point where we’ll start commercialising our product.

 

**Q3: Now, CellPlan is obviously a total novel product and the fantastic news there
is that you’ve already signed up a leading stem cell storage facility through which
you’ll roll this product out. How is the lead up to the launch going?**

**A3**: So, we are just taking the final steps to launch the product and what I 
mean by the final steps is just finalising all of the aspects of our marketing approach.
That includes our e-commerce website that we have developed in such a way that we
are able to explain the benefits of storing stem cells but also all the details 
of the insurance policy itself and all of the services that we are including in 
CellPlan including a app with medical opinion service and a medical concierge service
as well. So, we have the ability, through our platform, to receive the applicable
details, to conduct the health questionnaire, to collect payments and also to issue
the insurance policy digitally. So, this is something that we have developed since
the IPO and then we are finalising all of the aspects of the digital marketing approach
from our side and the marketing approach from our partner the cord blood bank BioVault
in the UK so that we can start to offer CellPlan to new clients that are looking
to store stems with BioVault and also to our existing clients that have already 
stored their baby’s stem cells but do not have insurance to cover the costs associated
with treatment. So, we are almost ready to launch the product and Widecells Group
should have news very soon.

 

**Q4: Aside from your strategic product offering, Widecels Group obviously have 
a very strong Board behind you including the recent appointment from the former 
Director at Apple Education. Can you talk us through them and what their responsibilities
are?**

**A4**: Since I started Widecells I always had this vision of before getting our
products to market, to do something that perhaps slightly different from what most
start-up companies do which is going straight to market, testing the product and
then refining them and in the healthcare industry, things normally don’t work like
that. We test our products first, we need to refine our quality management and we
need to have high profile members in our team so that we can gain trust from partners
and from clients globally because what we are bringing to the table is a global 
proposition.

With that in mind, we spent most of the time product development and for that I 
always look for the best so for example, when we were half way through the process
of developing CellPlan, the insurance plan, we had been fortunate to have Dr Marilyn
Orcharton on board. She is the founder of DenPlan in the UK, the largest dental 
payment specialist plan, a company she started in the early 80’s and was sold last
year for around £200 million so she came on board as Non-Executive Director but 
she also helped us with the development of CellPlan, anticipating potential problems
and if we have a very robust product it is because Marilyn is on board.

We have Dr Peter Hollands, which is one of renowned stem cell specialists in the
world, he has enabled us to identify this laboratory at the University of Manchester
and also to develop a plan where we could have a high quality standard facility 
for a minimum investment in comparison to the average in the industry globally. 
He has also opened doors for us to start doing our first contract research project
such as the one we have in place at the moment, that is already starting to generate
revenue with a Californian medical device company.

Now, more recently, one of the projects that we have, perhaps, advanced around 10-
12 months is the WideAcademy division. WideAcademy is where we want to provide accurate
scientific and medical information, not only to the healthcare community but also
to potential clients who are looking for stem cell treatments or also to store their
baby’s stem cells. Again, what I was looking for was someone that had very good 
understanding of what’s called the adtech space and could take advantage of the 
difficult marketing tools that are available today so that we can have curated content
so that we can reach doctors all over the world, within different specialties and
also potential clients. Someone like Alan Greenberg, who has done that for Apple
Education, where one of the podcasts he developed reached 3 billion downloads just
last week and I think it’s an unbelievable opportunity. So, looking at the thing
we’ve brought together, it’s an all-star team and we are in a mission to make stem
cell treatment accessible and affordable globally and we are all involved in this
mission and that’s why they’re on board.

Share on:
